Floatz logo

18F-ASIS

Non-Hodgkin's Lymphoma

Memorial Sloan Kettering Cancer CenterPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BBB
Zofran
MEI Pharma, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
Thymus NeoplasmsDormant
CCC
Indicative ·
53 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →